Stock Watch: Amphastar’s Turn Away From Generics
Specialty Pharma Treads A Precarious Path Between Pharma And Generics
Executive Summary
Amphastar’s 2020 financial results included its best ever quarter and a different revenue pattern from most pharma and generic companies. Its evolving product mix and marketing campaigns were two reasons for its performance.